Maharashtra FDA Cancels Cipla's Pune Warehouse Drug Licences Over Alleged Packaging, Storage & Record Violations
Mumbai, Oct 2: The Maharashtra Food and Drug Administration (FDA) on Friday said it has cancelled the drug sale and distribution licences of Cipla Pharma & Life Sciences Ltd's carrying and forwarding (C&F) warehouse at Wadki in Pune following detection of alleged violations. Fresh action after court directions The action was taken after completion of fresh proceedings in compliance with the…
The Maharashtra Food and Drug Administration (FDA) has revoked the drug sale and distribution licences of Cipla Pharma & Life Sciences Ltd's carrying and forwarding (C&F) warehouse in Pune. This decision was made following complaints of alleged violations in packaging, storage, documentation and record-keeping, as directed by the Bombay High Court.
The FDA's action followed a fresh set of proceedings in August 2022, when the facility was previously sanctioned for the same violations. On September 4, the FDA issued a revised show-cause notice to the company, which replied on September 11 and was granted a personal hearing on September 21. The licensing authority considered the company's response, their submissions, inspection findings, available records and applicable legal provisions before making the latest decision.
The FDA's concerns centered around Reactin Plus, a Schedule H drug. During the warehouse inspection, the regulator found the drug's packaging claiming it as an analgesic, promoting its use for various conditions including headaches, muscle pain, backache, joint pain, sprain, body ache and toothache. The FDA deemed these claims non-compliant with statutory provisions, stating they constituted misbranding under the Drugs and Cosmetics Act, 1940.
Additionally, the FDA noted deficiencies in storage and warehouse management, such as the absence of the required Form 35 inspection book, medicines kept directly on the floor, dust accumulation on drug stocks, and expired medicines lacking a designated area clearly marked 'Expiry-Not for Sale'.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.